investigating osimertinib for brain activity in egfr-mutated lung cancer
Published 5 years ago • 346 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib
-
2:02
case 4: upfront osimertinib in metastatic egfr nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:44
combination therapy with osimertinib for egfr nsclc - targeted therapies in lung cancer 2023
-
3:17
osimertinib in egfr-positive nsclc with brain metastases
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
1:02
examining data for osimertinib in egfr lung cancer
-
3:20
egfr mutated nsclc disease progression on osimertinib - 2022 program: targeted therapies forum
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
2:50
sequencing with osimertinib in egfr-mutated nsclc
-
4:39
defining osimertinib’s value in treating egfr nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
1:15
osimertinib improves survival in egfr nsclc, poses new challenges for resistance